SLC6A19 and Hartnup disease: JNT-517 caused a dose-dependent increase in urinary Hartnup amino acids in both SAD and MAD cohorts, reproducing the aminoaciduria signature observed in Hartnup disorder resulting from loss-of-function mutations in SLC6A19 and corroborating the pharmacology of SLC6A19 inhibition in mice.